Magrath George, the Chief Executive Officer of Opus Genetics, Inc., has reported a significant transaction involving the sale of shares to meet tax obligations. This transaction, which occurred on October 23, 2026, highlights the financial management strategies employed by executives in the pharmaceutical preparations industry.

According to the recent filing with the SEC, George sold 9,591 shares of common stock at a price of $3.585 each. The filing indicates that this sale was executed automatically to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units. Notably, this transaction does not represent a discretionary trade by George.

Background

Opus Genetics, Inc. is a company focused on pharmaceutical preparations, specifically in the life sciences sector. The company is based in Durham, North Carolina, and has undergone several name changes in its history, previously known as Ocuphire Pharma, Inc. and Rexahn Pharmaceuticals, Inc. The recent filing is part of a series of disclosures made by George, with the latest being on October 27, 2026.

What the Filing Says

The SEC filing, accession number 0001140361-26-040893, provides details of the transaction, stating, "The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Issuer to satisfy tax withholding obligations that arose in connection with the vesting and settlement of restricted stock units." This reflects the regulatory requirements that executives must adhere to when managing their stock holdings.

Impact

This transaction may affect stakeholders, including investors and employees of Opus Genetics, as it reflects the company's approach to executive compensation and tax management. The sale of shares by a CEO can influence perceptions of the company's financial health and governance practices in the pharmaceutical sector.

What's Next

The filing does not say what happens next.